Biotie Therapies - Company Announcement

Biotie renews SEDA agreement with YA Global, securing committed standby equity of up to 20 million euro

BIOTIE THERAPIES CORP.             STOCK EXCHANGE RELEASE     3 AUGUST 2012  AT
8.50 A.M.

Biotie renews SEDA agreement with YA Global, securing committed standby equity
of up to 20 million euro

Biotie has renewed its Standby Equity Distribution Agreement ("SEDA") with YA
Global Master SPV Ltd. ("YA Global") a fund managed by Yorkville Advisors, LLC
of Jersey City, New Jersey, USA ("Yorkville"). Under the terms of the agreement,
Biotie has the option under certain conditions to take up YA Global's commitment
to subscribe and pay for ordinary Biotie shares in multiple tranches up to a
total value of 20 million euro over the period until November 2015.

The purpose of the Standby Equity Distribution Agreement is to secure the
financing of Biotie's working capital in the short and medium term. It remains
at the sole and exclusive discretion of Biotie to exercise this option.

Timo Veromaa, Chief Executive Officer of Biotie commented, "We have found the
SEDA with Yorkville an innovative and flexible financing tool. While we have not
used the facility extensively in the past, and do not plan to use it in the near
term, it is prudent in these financial markets to have access to multiple
sources of capital and so we are pleased to renew this arrangement for a further
3 years."

The terms of the renewed SEDA follow the previous SEDA agreement published on
23 October 2009. Detailed information on the terms of this agreement can be
found at www.biotie.com/investors.  In consideration of the committed standby
equity Biotie will pay to YA Global a one-time commitment fee of EUR 200,000
either in cash or shares

Biotie will, as a general rule, publish a separate stock exchange release every
time the SEDA instrument is used once the pricing of the respective shares has
been determined.

In Turku, 3 August 2012

Biotie Therapies Corp.

Timo Veromaa
President and CEO

For further information, please contact:

Panu Miettinen
CFO
email: panu.miettinen@biotie.com
Tel: +358 2 274 8900

Virve Nurmi, IR Manager
tel. +358 2 274 8900, email: virve.nurmi@biotie.com
www.biotie.com

Distribution:
NASDAQ OMX Helsinki Ltd
Main Media

About Biotie

Biotie is a specialized drug development company focused on the development of
drugs for neurodegenerative and psychiatric disorders (e.g. Parkinson's disease,
Alzheimer's disease and other cognitive disorders, alcohol and drug dependence
(addiction) and post traumatic stress disorder), and inflammatory and fibrotic
liver disease.The company has a strong and balanced development portfolio with
several innovative small molecule and biological drug candidates at different
stages of clinical development. Biotie's products address diseases with high
unmet medical need and significant market potential.

Biotie has a strategic collaboration with UCB Pharma S.A. covering tozadenant
for Parkinson's disease. The Marketing Authorization Application for Biotie's
most advanced product, SelincroTM (nalmefene) for alcohol dependence was filed
in the EU by our partner H. Lundbeck A/S and was accepted for review by the
European Medicines Agency in December 2011. Biotie shares are listed on NASDAQ
OMX Helsinki Ltd.






[HUG#1631434]